Iambic Therapeutics, an AI-enabled cancer drug developer, priced a $150 million IPO to fund clinical development of internally discovered oncology programs. The company’s strategy is to use “molecular superintelligence” to accelerate discovery and move assets into the clinic, with IPO proceeds earmarked for advancing its wholly owned pipeline. The IPO follows a broader wave of young biotechs raising capital on AI-enabled platform claims and provides near-term liquidity for Phase 1 and preclinical-to-clinic transition work. Iambic also cites existing R&D alliances, including collaborations with Bayer and AbbVie. For investors and partners, the IPO is a test of whether AI-discovery narratives can translate into credible clinical timelines and capital-light project execution. The launch adds to a tightening market where capital is increasingly directed to companies that can pair early scientific differentiation with measurable clinical or regulatory progress within investor time horizons.